Therefore, it makes sense for an antibody that targets HER2—such as the aforementioned zanidatamab recently approved under FDA breakthrough therapy designation for the treatment of advanced CCA—to be conjugated with a cytotoxic payload to increase the potency of the anticancer regimen. This evidence concerns the gene ERBB2 and cholangiocarcinoma.